PLENARY KEYNOTE SESSION

Wednesday, 18 November | 15:45 – 16:50

Chairperson's Remarks
Jennifer R. CochranJennifer R. Cochran, PhD, Macovski Professor of Bioengineering, Stanford University; Co-Founder, Red Tree VC


The Making of Multispecific Antibodies—A Clinical Perspective
Roland KontermannRoland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart

  • How has the field of multispecific antibodies evolved in recent years?
  • What are the modes of action utilised by multispecific antibodies?
  • What are the frequently used targets and target combinations?
  • What are the emerging applications?

The Future of T Cell Engagers
Patrick BaeuerlePatrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.

  • How will in vivo CAR T cells impact TCEs?
  • Will we ever see CAR T cells approved in solid tumour indications?
  • Which ongoing developments of TCEs are most relevant? (e.g., combo with SoC, multitargeting, conditional)

FIRESIDE CHAT: Emerging Modalities and the Future of Antibody Engineering
PANEL MODERATOR:
Jennifer R. CochranJennifer R. Cochran, PhD, Macovski Professor of Bioengineering, Stanford University; Co-Founder, Red Tree VC

  • What it takes to bring modalities to fruition, business aspects
  • Combinations and sequential therapies
  • Cross-modalities
  • How might peptides be combined with antibodies? or oligos?
  • Addressing unmet medical need

PANELISTS:
Roland KontermannRoland Kontermann, PhD, Professor & Deputy Head, Biomedical Engineering, University of Stuttgart


Patrick BaeuerlePatrick Baeuerle, PhD, Chief Scientific Advisor, Cullinan Therapeutics, Inc.


Ulrike PhilipparUlrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine


TRACK KEYNOTES

Andreas G. PlueckthunEvolution of Design and Design of Evolution
Andreas G. Plueckthun, PhD, Professor and Head, Biochemistry, University of Zurich


Hitoshi KatadaEmpowering Next-Generation Antibodies: Synergy of Conditional Activation and Fc Engineering
Hitoshi Katada, PhD, Head of Biologics Engineering, Chugai Pharmaceutical Co. Ltd.


Charlotte M. DeaneData and Baselines in AI for Antibody Design
Charlotte M. Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Executive Chair, Engineering and Physical Sciences Research Council (EPSRC)


Marjolein van EgmondUnlocking New Horizons: Anti-CD89 Antagonist Antibodies as Game-Changers in Treatment of IgA-Driven Autoimmune Disease
Marjolein van Egmond, PhD, Professor, Oncology and Inflammation, Surgery/Molecular Cell Biology and Immunology, Amsterdam UMC


Yang ShenA Novel Approach to Enhance Tissue Specific Gene Delivery
Yang Shen, PhD, Executive Director, Antibody Engineering, Bispecifics, Regeneron


Shohei KoideTargeting the Adhesion Class of GPCRs with Biologics for Cancer Therapy
Shohei Koide, PhD, Professor, Biochemistry & Molecular Pharmacology, New York University School of Medicine; Perlmutter Cancer Center, NYU Langone Health


Arvind SivasubramanianDevelopability Profiling, off-Target Screening, and CDR Engineering to De-Risk Therapeutic Antibodies
Arvind Sivasubramanian, PhD, Director, Computational Biology & Platform Technologies, Adimab LLC


Ulrike PhilipparMultispecific T Cell Engagers and Co-Stimulation Combinations for the Treatment of Cancer Patients
Ulrike Philippar, PhD, Vice President Oncology, Global Head of Discovery, Johnson & Johnson Innovative Medicine


Nicolas FischerTumour-Selective CD47 Targeting for the Treatment of Platinum-Resistant Ovarian Cancer
Nicolas Fischer, PhD, CEO, Light Chain Bioscience


Aude SegalinyEnhancing Safety to Unlock Efficacy: A Novel Class of Conditionally Activated TCEs for Solid Tumours
Aude Segaliny, PhD, Vice President, Research & Development, Amberstone Biosciences


Robbie G. MajznerEngineering More Effective CAR-T Cells by Co-Opting T Cell Signaling Networks
Robbie G. Majzner, MD, Dana Farber Cancer Institute


Cedrik M. BrittenTargeting PRAME+ Cancers: Clinical Progress across TCR T Cell Therapy and Bispecific Approaches
Cedrik M. Britten, CMO, Immatics Biotechnologies GmbH


Hristo SvilenovPredictive Strengths and Critical Gaps in Next-Generation Developability Workflows
Hristo Svilenov, PhD, Associate Professor, TUM


Alexey RakStructural Biology at the Forefront of Biotherapeutics: Cryo-EM, AI, and Complex Modalities
Alexey Rak, PhD, Head, Biostructure and Biophysics, Sanofi


Patrick GaridelWhat Have We Learned from a Decade of Research into Polysorbate Degradation?
Patrick Garidel, PhD, Head, Process, Purification, and Pharma Development, Biopharma, Boehringer Ingelheim Pharma GmbH, Germany


Nicola Burgess-Brown"EXPERT" A Structured Framework for Capturing Protein Expression and Purification Data to Develop Machine Learning Models
Nicola Burgess-Brown, PhD, Professorial Research Fellow, UCL, London; COO, Protein Sciences, Structural Genomics Consortium


Gyun Min LeeRMCE-Enabled Genome-Wide CRISPR Screening for High-Performance CHO Cell Engineering
Gyun Min Lee, PhD, Professor, Graduate School of Engineering Biology, KAIST


Pietro SormanniDisulphide and Sequence-Encoded Conformational Priors Guide Nanobody Structure Prediction
Pietro Sormanni, PhD, Associate Professor & Royal Society University Research Fellow, Chemical Engineering, Imperial College London


Peter ClarkReal-World Progress, Challenges, and Opportunities for AI in Protein and Peptide Discovery
Peter Clark, PhD, Vice President, Computational Drug Design, Novo Nordisk Inc.


Christian HeinisDeveloping Membrane-Permeable Cyclic Peptides for Targeting Intracellular Proteins and for Oral Applications
Christian Heinis, PhD, Associate Professor, Lab of Therapeutic Proteins & Peptides, EPFL Lausanne


* As of 15 June. Please see individual agenda pages for most up-to-date agenda.